Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Platinum International Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"The Fund capitalized on risk contango conditions by rotating towards quality defensive pharmaceutical stocks while maintaining overweight China and Europe positions. Strong Chinese technology performance and defensive positioning protected capital during March tariff volatility."
The Platinum International Fund delivered a solid start to 2025, returning +0.2% while protecting investor capital in volatile markets as the benchmark fell nearly 2%. The Fund benefited from overweight positions in China, Europe and the UK, with Chinese stocks strongly outperforming in February and early March. Portfolio manager Ted Alexander, who took over on March 3rd, identified a risk contango opportunity where safer, high-quality businesses now offer higher expected returns than speculative technology stocks due to valuation disparities. This led to strategic rotation towards defensive pharmaceutical manufacturers including AbbVie, AstraZeneca, Merck and Novartis. The Fund maintained strong overweight positioning in China based on continued economic recovery while adding downside protection as markets fell in March on tariff concerns. Looking ahead, the portfolio is well-positioned for potential US economic shocks from tariff policies, though monitoring contagion effects into Europe and China remains important. The base case assumes a weaker US economy with inflation shock, while the rest of the world faces muted inflation but reduced demand from the US.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction evident in specific positioning decisions, clear articulation of risk contango thesis, maintained overweight China despite volatility, and decisive rotation to pharmaceuticals. Strong analytical framework supports positioning choices.
Growth Outlook
The manager expresses cautious optimism about opportunities but acknowledges significant headwinds from tariff uncertainty, potential US economic weakness, and inflation shocks. The outlook balances opportunity identification with defensive positioning.
Risk Appetite
The Fund adopted a more defensive stance with higher cash levels, rotation to defensive pharmaceuticals, and positioning to protect against US shocks. However, maintained overweight positions in China and Europe showing selective risk-taking.
Capital Deployment
The Fund increased cash levels for defensive purposes and took profits on strong Chinese performers, indicating modest de-risking. However, continued to add to pharmaceutical positions and maintained overweight allocations.
Forward Guidance
Forward guidance is cautious with focus on monitoring contagion effects and base case scenario of weaker US economy. However, the manager identifies specific opportunities in risk contango and maintains conviction in Chinese recovery.
Language Signal
Language is balanced with terms like 'solid start', 'well-positioned', and 'opportunities' offset by 'uncertainty', 'volatility', and 'shock'. Slight positive bias from opportunity identification and defensive positioning confidence.
Perceived Risk
High awareness of tariff uncertainty, potential US economic weakness, inflation shocks, and contagion effects. Explicit discussion of positioning for protection against various shock scenarios indicates elevated risk perception.
Opportunity Density
Manager identifies specific opportunities in risk contango conditions, attractive pharmaceutical valuations, and continued Chinese recovery. Selective opportunity identification in defensive sectors and specific geographies.
Time Horizon
Focus on fundamental active management, long-term success, and positioning for medium-term economic scenarios. Emphasis on quality businesses and sustainable competitive advantages suggests patient capital approach.
